Trial Profile

A Single-arm, Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Sintilimab and CAPEOX as 1L Treatment for Advanced Unresectable or Metastatic G/GEJ Cancer (FUNCTION Research)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Fruquintinib (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms FUNCTION Research

31 Dec 2024 Trial design is discussed in an abstract published at 49th European Society for Medical Oncology Congress.
29 Aug 2024 According to an Innovent Biologics media release, trial in progress poster will be presented at the European Society of Medical Oncology (ESMO) from Sept 13-17, 2024, in Barcelona, Spain.
28 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com